



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

ASX Announcement

19 August 2011

CathRx Signs Non-Binding Term Sheet



CathRx Ltd (ASX: CXD) advised on 11 July 2011 that negotiations for the licensing of CathRx products were focused on two prospective licensees.

CathRx announces that it has now signed a detailed term sheet with one prospective licensee for the development and commercialisation of innovative CathRx catheters in Europe. The parties will now begin the process of due diligence and negotiations for the purpose of entering into a definitive commercial agreement that reflects the term sheet.

CathRx's CEO, Mr. Jeff Goodman said, "I am extremely pleased with the progress of the negotiations and look forward to a prompt signing of a definitive agreement".

Until due diligence is satisfactorily completed and a definitive agreement is entered into, the terms of the term sheet remain non-binding with the exception of confidentiality.

CathRx is continuing its discussions with the other prospective licensee.

End

About CathRx

CathRx is a medical device company which designs and manufactures reprocessable cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to cost effectively treat patients with speed, safety and precision.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Cardiologists worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

For further information:

Jeffrey Goodman
CathRx Chief Executive Officer
Telephone: 02 9397 5700

Amanda Wong
CathRx Chief Financial Officer
Telephone: 02 9397 5700